Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
4 hedge funds and large institutions have $2.95K invested in Altamira Therapeutics Ltd in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
15% less capital invested
Capital invested by funds: $3.47K → $2.95K (-$515)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.62K |
| 2 |
Morgan Stanley
New York
|
+$1.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1.9K | +$2.62K | +1,711 | New |
|
|
2
Morgan Stanley
New York
| $1.04K | +$1.43K | +933 | New |
|
3
Group One Trading
Chicago,
Illinois
| $16 | – | – | – |
|
|
LI
4
LRI Investments
Palm Beach Gardens,
Florida
| $1 | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | -$3.44K | -1,660 | Closed |
|
CYTO Hedge Fund Activity: Q2 2024 in Review
4 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2024, worth a combined $2.95K — down 15% from $3.47K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CYTO positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $2.62K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3.44K sold.
- 4 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2024, up from 3 in Q1 2024.
- Funds reported $2.95K of Altamira Therapeutics Ltd stock for Q2 2024, down 15% quarter-over-quarter.
- 2 funds opened new Altamira Therapeutics Ltd positions in Q2 2024 and 1 closed out, a net change of +1 holder.
- The largest Altamira Therapeutics Ltd buyer in Q2 2024 was UBS Group, an estimated $2.62K added.
- The largest Altamira Therapeutics Ltd seller in Q2 2024 was Tower Research Capital (TRC), an estimated $3.44K sold.
Based on aggregated 13F filings for Q2 2024.